https://orcid.org/0000-0002-0921-3083
References
- Antoni S , FerlayJ, SoerjomataramIet al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol.71(1), 96–108 (2017).
- Galsky MD , ChenGJ, OhWKet al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann. Oncol.23(2), 406–410 (2012).
- Galsky MD , HahnNM, RosenbergJet al. Treatment of patients with metastatic urothelial cancer ‘unfit’ for cisplatin-based chemotherapy. J. Clin. Oncol.29(17), 2432–2438 (2011).
- Lopez-Beltran A , CimadamoreA, BlancaAet al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers (Basel).13(1), 131 (2021).
- Lee FC , HarrisW, ChengHHet al. Pathologic response rates of gemcitabine/cisplatin versus methotrexate/vinblastine/adriamycin/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer. Adv. Urol.2013, 317190 (2013).
- Dash A , PettusJA, HerrHWet al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer.113(9), 2471–2477 (2008).
- Yuh BE , RuelN, WilsonTGet al. Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. J Urol.189(5), 1682–1686 (2013).
- Hennes ER , Dow-HillgartnerEN, BergsbakenJJ, PiccoloJK. PARP-inhibitor potpourri: a comparative review of class safety, efficacy, and cost. J. Oncol. Pharm. Pract.26(3), 718–729 (2020).
- Wang Y-Q , WangP-Y, WangY-Tet al. An update on poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy. J. Med. Chem.59(21), 9575–9598 (2016).
- Rimar KJ , TranPT, MatulewiczRSet al. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer123(11), 1912–1924 (2017).
- Turner N , TuttA, AshworthA. Hallmarks of “BRCAness” in sporadic cancers. Nat. Rev. Cancer.4(10), 814–819 (2004).
- Brönimann S , LembergerU, BruchbacherAet al. Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. Curr. Opin. Urol.30(4), 519–526 (2020).
- Pezaro C . PARP inhibitor combinations in prostate cancer. Ther. Adv. Med. Oncol.12, 1758835919897537 (2020).
- Adashek JJ , JainRK, ZhangJ. Clinical development of PARP inhibitors in treating metastatic castration-resistant prostate cancer. Cells.8(8), 860 (2019).
- Teo MY , BamburyRM, ZaborECet al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin. Cancer Res.23(14), 3610–3618 (2017).
- Plimack ER , DunbrackRL, BrennanTAet al. Defects in DNA Repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol.68(6), 959–967 (2015).
- Jian W , XuH-G, ChenJet al. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. Anticancer Drugs.25(8), 878–886 (2014).
- LaFargue CJ , DalMolin GZ, SoodAK, ColemanRL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol.20(1), e15–e28 (2019).
- Yan F , JiangQ, HeM, ShenP. PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis. Future Oncol.17(18), 2381–2393 (2021).